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Results published in the late 50's and early 60's
marked the beginning of the stem cell era. Sem-
inal contributions was made by Ford et al. in
1956 and Till and McCulloch in 1961, demon-
strating that lethally irradiated mice could be
rescued with cells from freshly isolated bone
marrow (10) and that BM cells formed spleen
clonies (CFU-S) following transplantation to ir-
radiated recipients (30), respectively. 
There is no uniform definition of stem cells, but
they are characterized by being i) undifferenti-
ated, ii) having the potential to produce special-
ized differentiated cells for a long period of
time, and iii) postulated to be capable of main-
taining or expanding the number of stem cells
(i.e. self-renew).
There are different types of stem cells that best
can be described in the context of normal hu-
man development (23). A fertilized egg is
totipotent, meaning that its potential is total,
and as the fertilized egg divides all the cells in
the embryo remain totipotent until the fertilized
egg has reached the 8/16-cell stage. In theory,
and to some extent in practice, an 8-cell embryo
can be divided into eight single cells, and each
cell has the potential of generating an individ-
ual if implanted in a woman's uterus. This tech-
nique is called cloning by "embryo-splitting"
and has been performed in several species in-
cluding monkeys (5). 
Approximately five days after fertilization the
totipotent cells have differentiated and started
to form a hollow sphere of cells called a blasto-
cyst. The blastocyst has an outer layer of cells,
and inside there is a cluster of cells called the
"inner cell mass". A few of the cells in the inner
cell mass will develop into the foetus, whereas
the rest will form the placenta and other sup-
porting tissues needed for foetal development
in the uterus. The cells giving rise to the foetus,
are called pluripotent embryonic stem cells,
since they can form every cell type in the body.
However, they cannot form an organism be-
cause they are unable to give rise to extra em-
bryonic tissue essential for normal develop-
ment in the uterus. Embryonic stem (ES) cell
lines were isolated from mice in 1981 (9, 20),
monkeys in 1995 (29), and humans in 1998
(28). 
Pluripotent stem cells are also found in certain
regions of the developing fetus and have been
derived from 5-9 weeks old aborted human fe-
tuses (26). These cells are commonly termed
embryonic germ (EG) cells because they are
derived from primordial germ cells found at the
genital ridges in developing fetuses.
The pluripotent stem cells differentiate further
into cells commonly called multipotent stem
cells. These stem cells are considered commit-
ted to certain cell lineages. Examples of multi-
potent stem cells are those producing blood,
nerve and muscle cells. Multipotent stem cells
are present in the adult individual as well as the
fetus and umbilical cord. 
Stem cells from adults
It has been suggested that adults contain 20 dif-
ferent types of stem cells. Hematopoietic
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(blood forming) stem cells have been investi-
gated for several decades and is currently by far
the best characterized stem cell system. Until
recently it was considered a fact that, for exam-
ple, hematopoietic stem cells did not have the
potential to differentiate into cells of other
types than the cells constituting the blood sys-
tem. The same applied to stem cells in other tis-
sues, such as the brain, muscle, endothelium,
liver etc. The established dogma has however
been challenged by recent findings suggesting
that multipotent stem cells have a broader dif-
ferentiation potential than previously thought.
For example it has been indicated that nerve
cells have changed their fate and started to pro-
duce functional blood cells (2) and vice versa
(22). Likewise, stem cells in skeletal muscle
have been proposed to generate blood (13) and
vice versa (18). Even more surprisingly, nerve
stem cells generated nearly all cell types in de-
veloping fetuses when transferred into the cav-
ity of blastocysts (8). 
A recent study indicates that even adult humans
might harbor cells resembling pluripotent em-
bryonic stem cells. Verfaillie and coworkers
(14) demonstrated that cells isolated from the
bone marrow could be cultured for prolonged
periods of time and differentiate both in vitro
and in vivo into a vide variety of seemingly nor-
mal cells. 
Although several reports indicate an ability of
multipotent stem cells to produce cells even
outside their normal limits, most of these find-
ings remain highly controversial. This is mainly
due to i) lack of reproducibility (4, 16, 21),  ii)
the effects have not been demonstrated at the
single cell level and iii) it has been demon-
strated that the reported findings might be arti-
facts of the methods used (27, 32).  
Embryonic stem cells
In order to establish embryonic stem cell lines,
the inner cell mass of blastocyst stage embryos
is cultured in the presence of serum and mitoti-
cally inactivated murine feeder layers (28).  Hu-
man embryonic stem cells have a population-
doubling time of about 36 hours and can be
propagated for prolonged periods in serum free
media supplemented with basic fibroblast
growth factor (bFGF). 
Human embryonic stem cells can, when in-
duced to differentiate, develop into a variety of
cell types. This property makes them valuable
as a model system to study the mechanisms reg-
ulating lineage commitment and differentia-
tion. In particular, the system enables detailed
studies of early development with regard to ex-
trinsic and intrinsic regulators as well as en-
abling gene knock-out/in studies not commonly
available in human model systems.
Stem cells in the clinic
Stem cells are currently only being used to a
limited extent in routine clinical practice. Bone
marrow transplantation of cancer patients is the
most known example. However, there is consid-
erable hope that stem cells can be utilized in the
treatment of a wide array of human disorders by
replenishing lost or unfunctional cells. Diseases
like Alzheimers, Parkinson, immune deficien-
cies, anemia and type I diabetes are all candi-
date diseases potentially suitable for stem cell-
aided therapy. A number of clinical trails with
adult as well as foetal stem cells are ongoing,
whereas clinical trails with embryonic stem
cells have not yet started. 
It is expected to take several years before em-
bryonic stem cells will be entering large-scale
clinical trials, since there are a number of hur-
dles needed to be overcome before embryonic
stem cells are ready for clinical trials. Firstly,
culture conditions enabling embryonic stem
cells to be cultured in the absence of serum or
other animal-derived factors, need to be estab-
lished. This is due to the risk of transmitting
disease-causing agents from animals to hu-
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mans. Secondly, only differentiated cells should
be transplanted. Undifferentiated embryonic
stem cells carry a risk of developing into ter-
atomas when transplanted into immunocom-
promised patients. Thirdly, mechanisms en-
abling the transplanted cells to be eliminated in
vivo are likely to be a prerequisite for treating
serious, but non-life threatening, diseases. If
something should go wrong with the trans-
planted cells, it will be of key importance to
have mechanisms enabling neutralization of the
transplanted cells. Fourthly, extensive animal
experimentation is required in advance of clin-
ical trials on humans. Animal trials are of im-
portance to evaluate toxic side effects and
preferably also clinical effect of the treatment.
Animal studies on human embryonic stem cells
(or derived cells thereof) can, however, be of
limited value due to the potential immunologi-
cal elimination of human cells in the animal and
lack of physiological responses due to species
differences. Finally, the transplanted cells must
be accepted by the recipient's immune system
to avoid being rejected. With regard to stem
cells this challenge can be overcome by a vari-
ety of means. Among the options used today are
i) using the patient's own stem cells, ii) cells
from a matched donor, and iii) generating large
banks of stem cells. Furthermore, stem cells
suitable for transplantation can potentially in
the future be obtained by iv) parthenogenesis
(6), v) generation of pluripotent stem cells by
somatic nuclear transfer (therapeutic cloning)
(7), or vi) by genetic engineering to generate
universal stem cell lines.
Murine embryonic stem cells, which have been
studied for several years, have demonstrated an
ability to differentiate into a number of cell
types. Human embryonic stem cells have also
demonstrated their potential to differentiate
into a variety of cell types (12, 28), whereas
only a limited amount of data is available on
their potential to differentiate into cells of a par-
ticular lineage. It has, however, been demon-
strated that even human embryonic stem cells
can differentiate with some degree of speci-
ficity into endothelial (19), nerve (3, 25, 33),
cardiomyocytes (17), insulin-producing (1) and
hematopoietic cells (15), thereby supporting
their proposed extensive clinical usefulness.
Conclusion
Whilst the ethical and political debates about
whether or not to allow the use of totipotent
cells in research have been fierce, the medical
breakthroughs have been rather limited. Four
years after the initial publication, we are still far
away from initiating clinical trials, and research
on embryonic stem cells remains a field in its
early days of basic research. The reason for lack
of progress can in part be explained by lack of
funding (24), limited availability of embryonic
stem cells lines (11), and national legislation
prohibiting research with human embryos (31).
Furthermore, patenting issues and secrecy may
have hampered the progress even further. 
It is difficult to predict the future usefulness of
embryonic stem cells for treating currently in-
curable human diseases on the basis of their
value as a tool in basic research. As mentioned
above, there are a number of challenges that
need to be solved before large-scale clinical tri-
als with embryonic stem cells can be started.
These challenges, and probably others not yet
known, must be solved before initiation of
large-scale clinical trials. Thus, embryonic
stem cells are not likely to be a part of routine
clinical practice in the foreseeable future. Their
immediate usefulness is therefore likely to be
limited to basic research and in various in vitro-
systems for several years. In contrast, stem cells
from adults are demonstrating potentials not
previously anticipated and are increasingly be-
ing tested in early-stage clinical trials. It re-
mains, however, to demonstrate if stem cells,
regardless of source, at all will be the method of
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choice in the future treatment of any human dis-
ease. 
A theoretical alternative to developing cells
suitable for transplantation from human stem
cells is to isolate transplantable cells directly
from animals (xenotransplantation). It can be
envisaged that xenotransplantation has a simi-
lar potential as human stem cells to treat a num-
ber of currently incurable diseases. Xenotrans-
plantation is, as human stem cells, however at
an early stage of basic research and several key
questions needs to be answered before large-
scale clinical trials can be initiated. Thus, to
make strong statements about the future clinical
usefulness of either human stem cells or xeno-
transplantation is currently premature, and as
both strategies are still promising, they should
actively be investigated further. 
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